Phase Ib/IIa Trial With AC01 in Patients With HFrEF - Trial NCT05642507
Access comprehensive clinical trial information for NCT05642507 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by AnaCardio AB and is currently Recruiting. The study focuses on Heart Failure With Reduced Ejection Fraction. Target enrollment is 80 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AnaCardio AB
Timeline & Enrollment
Phase 1/2
Feb 23, 2023
Nov 01, 2024
Primary Outcome
Safety and tolerability: Adverse Events (AEs),Safety and tolerability: Vital signs.,Safety and tolerability: Vital signs.,Safety and tolerability: Electrocardiogram (ECG).,Safety and tolerability: Clinical laboratory evaluations.
Summary
This is a randomized, double-blind, placebo-controlled two-part study with a multiple
 escalating dose phase followed by a cohort expansion phase to assess safety, tolerability,
 pharmacokinetics and pharmacodynamics of AC01 in patients with heart failure with reduced
 ejection fraction (HFrEF).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05642507
Non-Device Trial